159992 创新药
已收盘 09-11 15:00:00
资讯
新帖
简况
从“产品出海”到“体系出海”，上海创新药企复宏汉霖加速全球布局
上观新闻 · 17:19
从“产品出海”到“体系出海”，上海创新药企复宏汉霖加速全球布局
每周股票复盘：科兴制药（688136）将参加科创板创新药业绩说明会
证券之星 · 02:24
每周股票复盘：科兴制药（688136）将参加科创板创新药业绩说明会
麦科医药董事长王冰：以原创力决胜创新药新阶段
同花顺 · 09-12 09:31
麦科医药董事长王冰：以原创力决胜创新药新阶段
麦科医药董事长王冰： 以原创力决胜创新药新阶段
同花顺 · 09-12 04:40
麦科医药董事长王冰： 以原创力决胜创新药新阶段
麦科医药董事长王冰： 以原创力决胜创新药新阶段
同花顺 · 09-12 04:40
麦科医药董事长王冰： 以原创力决胜创新药新阶段
海南海药：紧盯创新药核心突破
证券之星 · 09-11 20:52
海南海药：紧盯创新药核心突破
创新药将迎数据催化窗口！OS、PFS、ORR还都分不清楚？速查指南来了！收藏备用
新浪基金 · 09-11 19:22
创新药将迎数据催化窗口！OS、PFS、ORR还都分不清楚？速查指南来了！收藏备用
重磅大会在前，创新药未有起色，什么情况？华宝基金港股通创新药ETF（520880）失守所有均线
新浪基金 · 09-11 19:17
重磅大会在前，创新药未有起色，什么情况？华宝基金港股通创新药ETF（520880）失守所有均线
昂利康创新药引进项目告吹：授权合作折戟背后，主业承压研发布局遇变数
新浪证券 · 09-11 15:35
昂利康创新药引进项目告吹：授权合作折戟背后，主业承压研发布局遇变数
一品红痛风创新药Ⅲ期临床达到主要终点 大中华区销售峰值预计达19.5亿元
新浪证券 · 09-11 15:34
一品红痛风创新药Ⅲ期临床达到主要终点 大中华区销售峰值预计达19.5亿元
通化金马：公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作
证券之星 · 09-11 11:51
通化金马：公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作
港股异动 | 创新药概念股持续调整 海外利率预期反复 2026国谈收官进入结果等待期
智通财经 · 09-11 11:08
港股异动 | 创新药概念股持续调整 海外利率预期反复 2026国谈收官进入结果等待期
国产创新药新适应症密集获批 “一药拓多域”重塑行业成长逻辑
格隆汇 · 09-11 07:32
国产创新药新适应症密集获批 “一药拓多域”重塑行业成长逻辑
2026年国家医保目录谈判收官：“三除外”落地，医保商保双轨并行，双目录如何重构创新药支付逻辑
华夏时报网 · 09-10
2026年国家医保目录谈判收官：“三除外”落地，医保商保双轨并行，双目录如何重构创新药支付逻辑
信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧
蓝鲸财经 · 09-10
信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧
东北证券：创新药BD和商业化持续兑现 CXO超预期，传统板块筑底拐点
智通财经 · 09-10
东北证券：创新药BD和商业化持续兑现 CXO超预期，传统板块筑底拐点
英硅智能(03696)：公司管线中领先的人工智能驱动候选创新药物 Rentosertib已在针对特发性肺纤维化的III期临床试验中完成首例患者入组
智通财经 · 09-10
英硅智能(03696)：公司管线中领先的人工智能驱动候选创新药物 Rentosertib已在针对特发性肺纤维化的III期临床试验中完成首例患者入组
对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药
新浪科技 · 09-09
对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药
亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%
证券之星 · 09-09
亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%
【券商聚焦】中邮证券维持翰森制药（03692）买入评级 指创新药成增长核心
金吾财讯 · 09-09
【券商聚焦】中邮证券维持翰森制药（03692）买入评级 指创新药成增长核心
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.803,"timestamp":1789110201000,"preClose":0.821,"halted":0,"volume":1086130325,"delay":0,"changeRate":-0.0219,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.018,"latestTime":"09-11 15:00:00","open":0.816,"high":0.819,"low":0.796,"amount":873000000,"amplitude":0.028,"askPrice":0.804,"askSize":17146,"bidPrice":0.803,"bidSize":51793,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.821,"symbolType":"fund","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":0.903,"lowLimit":0.739,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.102244,"marketValue":0,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","floatMarketCap":0},"requestUrl":"/m/hq/s/159992/","defaultTab":"news","newsList":[{"id":"2667681787","title":"从“产品出海”到“体系出海”，上海创新药企复宏汉霖加速全球布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2667681787","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667681787?lang=zh_cn&edition=full","pubTime":"2026-09-13 17:19","pubTimestamp":1789291195,"startTime":"0","endTime":"0","summary":"日前，上海创新药企复宏汉霖举办2026年开放日活动，围绕全球化布局、生物类似药商业化、创新研发及临床开发等话题披露最新进展。复宏汉霖执行董事、首席执行官朱俊博士介绍，截至目前，复宏汉霖已有4款产品获美国食品药品监督管理局（FDA）批准、5款获欧盟（EC）批准、8款获中国国家药品监督管理局（NMPA）批准，产品已惠及全球超过110万名患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872844911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872844911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","BK1161","HK0000165453.HKD","159992","IBBQ","06978","BK1574","HK0000306701.USD","LNGR","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667250744","title":"每周股票复盘：科兴制药（688136）将参加科创板创新药业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667250744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667250744?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:24","pubTimestamp":1789237455,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，科兴制药报收于18.98元，较上周的20.34元下跌6.69%。本周，科兴制药9月8日盘中最高价报21.97元。本周关注点公司公告汇总：科兴制药将于2026年9月16日参加科创板创新药行业集体业绩说明会。公司公告汇总科兴生物制药股份有限公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动形式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","159992","BK0239","688136","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666350832","title":"麦科医药董事长王冰：以原创力决胜创新药新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666350832","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666350832?lang=zh_cn&edition=full","pubTime":"2026-09-12 09:31","pubTimestamp":1789176660,"startTime":"0","endTime":"0","summary":"今年6月24日，麦科医药登陆港交所，实现了西北地区创新药企上市零的突破，上市首日涨幅超100%，香港公开发售部分获超1181倍认购，公司近日又获选纳入恒生综合指数成分股。从西安地下室一间2 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260912/c679847481.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260912/c679847481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666869577","title":"麦科医药董事长王冰： 以原创力决胜创新药新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666869577","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666869577?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:40","pubTimestamp":1789159200,"startTime":"0","endTime":"0","summary":"● 本报记者 何昱璞今年6月24日，麦科医药登陆港交所，实现了西北地区创新药企上市零的突破，上市首日涨幅超100%，香港公开发售部分获超1181倍认购，公司近日又获选纳入恒生综合指数成分股 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260912/c679844315.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260912/c679844315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666742955","title":"麦科医药董事长王冰： 以原创力决胜创新药新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666742955","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666742955?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:40","pubTimestamp":1789159200,"startTime":"0","endTime":"0","summary":"● 本报记者何昱璞今年6月24日，麦科医药登陆港交所，实现了西北地区创新药企上市零的突破，上市首日涨幅超100%，香港公开发售部分获超1181倍认购，公司近日又获选纳入恒生综合指数成分股。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20260912/c679844315.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260912/c679844315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666522670","title":"海南海药：紧盯创新药核心突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2666522670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666522670?lang=zh_cn&edition=full","pubTime":"2026-09-11 20:52","pubTimestamp":1789131125,"startTime":"0","endTime":"0","summary":"证券之星消息，海南海药09月10日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，贵公司半年报后净资产已经为负，营收连年下滑，扣非9年亏损，生存困难。氟非尼酮目前进入关键III期验证，派恩加滨IIB期，HY-001临床前期。创新药烧钱，贵公司资金短缺，为何不砍掉或者出售创新药管线，全力保壳？本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100047590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0239","06978","BK0146","BK1161","BK0070","159992","BK1574","000566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666798529","title":"创新药将迎数据催化窗口！OS、PFS、ORR还都分不清楚？速查指南来了！收藏备用","url":"https://stock-news.laohu8.com/highlight/detail?id=2666798529","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666798529?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:22","pubTimestamp":1789125720,"startTime":"0","endTime":"0","summary":"创新药重磅提示！就在周六，2026年WCLC将正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司将公布旗下核心产品临床数据。III期达到终点，意味着获批概率大幅提升，属于实质性大利好。临床试验中通常报告“中位OS”，即50%患者存活的时间。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。以优效性为目标的头对头试验证据级别最高。权重数据截至2026.8.31。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrw8907408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","MEDX","LNGR","159992","BK1161","BK1574","IBBQ","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529140","title":"重磅大会在前，创新药未有起色，什么情况？华宝基金港股通创新药ETF（520880）失守所有均线","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529140","media":"新浪基金","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666529140?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:17","pubTimestamp":1789125420,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhry5675751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","06978","159316","LNGR","159992","MEDX","520880","FLHK","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544925","title":"昂利康创新药引进项目告吹：授权合作折戟背后，主业承压研发布局遇变数","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544925","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544925?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"9 月 6 日，昂利康发布公告宣布终止与亚飞生物、亲合力的 IMD\u001e1005肿瘤抗体药物授权许可合作。02主业盈利出现下滑，创新转型面临双重考验创新药引进受挫的同时，昂利康主业经营已经显现压力。原料药业务是昂利康的基本盘，业绩下滑说明核心主业易受行业周期、市场供需波动冲击，自身抗周期能力有待加强。未来昂利康既要稳固原料药基本盘，也需要平衡好资金投入与管线风险，审慎推进授权引进类项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5384750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","MEDX","BK0239","LNGR","159992","BK1161","BK1574","002940","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544603","title":"一品红痛风创新药Ⅲ期临床达到主要终点 大中华区销售峰值预计达19.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544603","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544603?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:34","pubTimestamp":1789112040,"startTime":"0","endTime":"0","summary":"近日，一品红自愿披露关于痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点的公告。商业化权益方面，AR882为一品红自主研发的1类创新药，在大中华区拥有完整的开发、生产与商业化权益，且一品红具备成熟的自有慢病药商业化团队，无需对外支付销售分成。结合0.70的临床成功概率，最终AR882大中华区痛风适应症管线的风险调整净现值约为5.5亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-11/doc-inirmvzz2155509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","06978","159992","300723","BK0239","MEDX","BK1161","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666484915","title":"通化金马：公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2666484915","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666484915?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:51","pubTimestamp":1789098666,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)09月10日在投资者关系平台上答复投资者关心的问题。投资者提问：新药价格何时公布？通化金马回复：您好，公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作，首发价格定价以各省价格平台公示数据为准。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100024958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000766","BK0077","06978","BK0060","BK0239","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股异动 | 创新药概念股持续调整 海外利率预期反复 2026国谈收官进入结果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666510786?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE0008368742.USD","LU1960683339.HKD","LU0880133367.SGD","LU2097828557.USD","01093","MCRO","LU2097828474.EUR","LU0326950275.SGD","BK4585","IBBQ","LU1226287792.SGD","BK1589","LU2328871848.SGD","VXUS","LU0072913022.USD","01801","BK1161","LU1969619763.USD","IE0008369823.USD","06978","LU2488822045.USD","KURE","LNGR","IE00BZ08YT58.USD","KCAI","LU1831875114.USD","159992","LU0455707207.USD","LU2097828805.USD","LU0067412154.USD","MEDX","LU2242644610.SGD","LU0501845795.SGD","WRTH","LU1226288170.HKD","BK1515","02157","IE00B5MMRT66.SGD","LU1188198961.HKD","LU0244354667.USD","LU1328277881.USD","LU1807302812.USD","09995","LU1226287875.USD","LU1813983027.USD","LU0149534421.HKD","PEVC","LU1008478684.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511370","title":"国产创新药新适应症密集获批 “一药拓多域”重塑行业成长逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511370","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666511370?lang=zh_cn&edition=full","pubTime":"2026-09-11 07:32","pubTimestamp":1789083145,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","IBBQ","LNGR","MEDX","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560028","title":"2026年国家医保目录谈判收官：“三除外”落地，医保商保双轨并行，双目录如何重构创新药支付逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666560028?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午，北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门，历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布，2027年1月1日起统一执行。五天时间里，124个目录外药品先后完成基本医保谈判竞价，12个创新药冲击商保创新药目录价格协商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1161","IBBQ","MEDX","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重启H股IPO，创新药收入站上半壁江山，仍存单品依赖隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666648561?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4127","159992","FRHC","IBBQ","BK1574","LNGR","BK0028","BK0196","BK1161","BK0188","002294","06978","BK0239","KCE","BK0187","BK0183","REDS","MEDX","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"东北证券：创新药BD和商业化持续兑现 CXO超预期，传统板块筑底拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666513175?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK1161","IBBQ","BK0183","MEDX","BK0188","WX","BK1574","LNGR","BK0028","BK0276","06978","000686","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696)：公司管线中领先的人工智能驱动候选创新药物 Rentosertib已在针对特发性肺纤维化的III期临床试验中完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666555270?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，公司管线中领先的AI驱动候选创新药物 Rentosertib，已于北京协和医院完成III期临床试验的首例患者入组及给药;同日，上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK，旨在阻断或逆转纤维化进程，为IPF患者提供具备疾病改善潜力的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","QQQX","QQA","MFIG","AIQU","LNGR","PSQ","CHAT","TQQY","TECY","LCLG","QSWN","NJAN","161631","IBBQ","03696","PBOT","CPNQ","QTOC","DQJN","OGIG","AIFD","AGIX","NOCT","FWD","MVPS","06978","NBDS","159992","GPIQ","GK","MEDX","IBBJ","PSYK","AIBU","VUSE","AQGX","TARK","QQQ","QMAR","BMED","WPAI","MDTX","TQQQ","CWC","KOMP","NJUL","NEWZ","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666356195?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","IBBQ","HK0000306685.HKD","LNGR","HK0000306701.USD","LU2322448957.HKD","LU2272731865.HKD","159992","LU1992135472.HKD","HK0000320223.HKD","PPH","BK4588","IBB","BK1574","BK1161","LU2473716301.USD","MEDX","LU2272731782.SGD","XPH","BK4585","LU1992135399.USD","HK0000165453.HKD","IE00B5TLWC47.USD","06978","LU2322448791.USD","LU2272731600.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581807","title":"亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581807","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581807?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:33","pubTimestamp":1788946428,"startTime":"0","endTime":"0","summary":"江苏亚虹医药科技股份有限公司近日发布《关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》。公告显示，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心视频结合网络互动方式召开，会议将就公司2026年半年度经营成果、财务状况等与投资者进行交流。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","BK0239","159938","688176","06978","159992","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458356","title":"【券商聚焦】中邮证券维持翰森制药（03692）买入评级 指创新药成增长核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458356","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666458356?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:32","pubTimestamp":1788939161,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，翰森制药 发布2026年中报，2026H1实现收入83.04亿元，同比增长11.7%；归母净利润42.58亿元，同比增长35.8%，利润高增部分得益于约6.31亿元的投资收益等一次性项目。创新药已成为公司增长的绝对核心。创新药收入达70.92亿元，同比增长15.4%，占总收入比重由去年同期的82.7%提升至85.4%。其中抗肿瘤领域收入54.73亿元，占总收入65.9%；非肿瘤领域收入28.31亿元，占总收入34.1%。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991138","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","KCE","LNGR","03692","MEDX","161027","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789299211848,"stockEarnings":[{"period":"1week","weight":-0.0497},{"period":"1month","weight":-0.1262},{"period":"3month","weight":0.091},{"period":"6month","weight":0.0113},{"period":"1year","weight":-0.1789},{"period":"ytd","weight":-0.0337}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}